In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 136-144

  Upton, A M ^a   Cho, S ^b   Yang, T J ^a   Kim, A Y ^b   Wang, Y ^b   Lu, Y ^c   Wang, B ^c   Xu, J ^c   Mdluli, K ^a   Ma, Z ^a   Franzblaub, S G ^b  

^a Global Alliance for TB Drug Development   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; DELAMANID; NITROIMIDAZOLE; PRETOMANID; TBA 354; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; 2-NITRO-6-(4-(TRIFLUOROMETHOXY)BENZYLOXY)-6,7-DIHYDRO-5H-IMIDAZO(2,1-B)(1,3)OXAZINE; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZINE DERIVATIVE; OXAZOLE DERIVATIVE; TBA-354;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CACO 2 CELL LINE; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG PROTEIN BINDING; ELIMINATION HALF-LIFE; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOSIS; ANIMAL; ANTIBIOTIC RESISTANCE; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; DRUG INTERACTION; FEMALE; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; TUMOR CELL LINE;

ANIMALS; ANTITUBERCULAR AGENTS; CACO-2 CELLS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZINES; OXAZOLES; TUBERCULOSIS;

EID: 84920176601     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03823-14     Document Type: Article

References (32)

1. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx.doi.org/10 .1126/science.1106753.
2. Palomino JC, Martin A. 2013. TMC207 becomes bedaquiline, a new anti-TB drug. Future Microbiol 8:1071-1080. http://dx.doi.org/10.2217 /fmb.13.85.
3. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF. 2012. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrugresistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 56:3271-3276. http://dx.doi.org/10.1128/AAC.06126-11.
4. Grosset JH, Ammerman NC. 2013. Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207). Expert Rev Anti Infect Ther 11:649-651. http://dx.doi.org/10.1586/14787210.2013.811848.
5. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. 2012. Delamanid for multidrugresistant pulmonary tuberculosis. N Engl J Med 366:2151-2160. http://dx .doi.org/10.1056/NEJMoa1112433.
6. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, Spigelman MK. 2012. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother 56:3027-3031. http://dx.doi.org/10 .1128/AAC.06125-11.
7. Moffett M, McGill MI. 1960. Treatment of trichomoniasis with metronidazole. Br Med J 2:910-911. http://dx.doi.org/10.1136/bmj.2.5203.910.
8. Mukherjee T, Boshoff H. 2011. Nitroimidazoles for the treatment of TB: past, present and future. Future Med Chem 3:1427-1454. http://dx.doi .org/10.4155/fmc.11.90.
9. Carroll MW, Jeon D, Mountz JM, Lee JD, Jeong YJ, Zia N, Lee M, Lee J, Via LE, Lee S, Eum SY, Lee SJ, Goldfeder LC, Cai Y, Jin B, Kim Y, Oh T, Chen RY, Dodd LE, Gu W, Dartois V, Park SK, Kim CT, Barry CE, III, Cho SN. 2013. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother 57: 3903-3909. http://dx.doi.org/10.1128/AAC.00753-13.
10. Ashtekar DR, Costa-Perira R, Nagrajan K, Vishvanathan N, Bhatt AD, Rittel W. 1993. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 37:183-186. http://dx.doi.org/10.1128/AAC.37.2.183.
11. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. 2006. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3:e466. http://dx.doi.org/10.1371 /journal.pmed.0030466.
12. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR. 2011. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 15:949-954. http://dx.doi.org/10 .5588/ijtld.10.0616.
13. Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL. 2011. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother 55:239-245. http://dx.doi.org/10.1128/AAC.00849-10.
14. Garcia-Contreras L, Sung JC, Muttil P, Padilla D, Telko M, Verberkmoes JL, Elbert KJ, Hickey AJ, Edwards DA. 2010. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother 54:1436-1442. http://dx.doi.org/10.1128/AAC.01471-09.
15. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966. http://dx.doi.org/10.1038/35016103.
16. Singh R, Manjunatha U, Boshoff HI, Ha YH, Niyomrattanakit P, Ledwidge R, Dowd CS, Lee IY, Kim P, Zhang L, Kang S, Keller TH, Jiricek J, Barry CE, III. 2008. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322:1392-1395. http://dx .doi.org/10.1126/science.1164571.
17. Manjunatha U, Boshoff HI, Barry CE. 2009. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol 2:215-218. http://dx.doi.org/10.4161/cib.2.3.7926.
18. Gurumurthy M, Rao M, Mukherjee T, Rao SP, Boshoff HI, Dick T, Barry CE, III, Manjunatha UH. 2013. A novel F(420)-dependent antioxidant mechanism protects Mycobacterium tuberculosis against oxidative stress and bactericidal agents. Mol Microbiol 87:744-755. http://dx.doi .org/10.1111/mmi.12127.
19. Dawson R, Diacon A. 2013. PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert Opin Investig Drugs 22: 927-932. http://dx.doi.org/10.1517/13543784.2013.801958.
20. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 2012. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380:986-993. http://dx.doi.org/10.1016/S0140-6736(12)61080-0.
21. Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 52:1522-1524. http://dx.doi.org/10.1128/AAC.00074-08.
22. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL. 2012. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 56:3114-3120. http://dx.doi.org/10.1128/AAC.00384-12.
23. Kmentova I, Sutherland HS, Palmer BD, Blaser A, Franzblau SG, Wan B, Wang Y, Ma Z, Denny WA, Thompson AM. 2010. Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). J Med Chem 53: 8421-8439. http://dx.doi.org/10.1021/jm101288t.
24. Collins L, Franzblau SG. 1997. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium . Antimicrob Agents Chemother 41:1004-1009.
25. Falzari K, Zhu Z, Pan D, Liu H, Hongmanee P, Franzblau SG. 2005. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother 49:1447-1454. http://dx.doi .org/10.1128/AAC.49.4.1447-1454.2005.
26. Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli K, Angulo-Barturen I, Dick T, Dartois V, Lenaerts AJ. 2012. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) 92:453-488. http://dx.doi.org/10.1016/j.tube.2012.07.003.
27. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG. 2007. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 51:1380-1385. http://dx.doi.org/10.1128/AAC.00055-06.
28. Godfrey K. 1985. Statistics in practice. Comparing the means of several groups. N Engl J Med 313:1450-1456. http://dx.doi.org/10.1056/NEJM1 98512053132305.
29. Hidalgo IJ1, Raub TJ, Borchardt RT. 1989. Characterization of the human colon carcinoma cell line (Caco-2) as amodel system for intestinal epithelial permeability. Gastroenterology 96:736-749.
30. Banker MJ, Clark TH, Williams JA. 2003. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967-974. http://dx.doi.org/10.1002/jps.10332.
31. Dutta NK, Alsultan A, Gniadek TJ, Belchis DA, Pinn ML, Mdluli KE, Nuermberger EL, Peloquin CA, Karakousis PC. 2013. Potent rifamycinsparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother 57:3910-3916. http://dx.doi.org /10.1128/AAC.00761-13.
32. Tasneen R, Williams K, Amoabeng O, Minkowski A, Mdluli KE, Upton AM, Nuermberger EL. 2015. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob Agents Chemother 59:129-135. http://dx.doi.org/10 .1128/AAC.03822-14.